Lupus

Leading arthritis charity calls for personalised care plans for people with musculoskeletal conditions

care plan musculoskeletal conditionPeople with musculoskeletal health conditions would be empowered if they had a care plan designed to support them in self-managing their condition and wellbeing, says a new report from Arthritis Research UK.
About 20% of people in the UK go to the doctor about a musculoskeletal condition such as arthritis every year. But only 12% of people with these conditions have a care plan to support them. Continue reading

New multitarget therapy for lupus nephritis shows promise

lupus nephritis drugs tacrolimus, mycophenolate mofetil steroids intravenous cyclophosphamide People with lupus nephritis could benefit from the use of a new multitarget therapy, says research published in the Annals of Internal Medicine.
The 24-week trial assessed the combination therapy that consisted of tacrolimus, mycophenolate mofetil and steroids, compared with intravenous cyclophosphamide and steroids, as an induction therapy for lupus nephritis. Continue reading

New turmeric-based formulation may release anti-inflammatory benefits throughout body

turmeric curcumin lupus inflammation arthritisOver-the-counter curcumin supplements might not get past your digestive system, according to some experts, but now new research has found that a modified form of the spice can release its anti-inflammatory qualities throughout the body.
Curcumin is a naturally occurring compound found in the spice turmeric that has been used for centuries in traditional Chinese medicine. Continue reading

Arthritis drugs may contribute to stroke death says new study

NSAID Cox-inhibitor stroke deathCommonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in Neurology.
COX-2 inhibitors are selective nonsteroidal anti-inflammatory drugs (NSAIDs) that include older drugs diclofenac, etodolac, nabumeton and meloxicam, as well as newer drugs called coxibs, including celecoxib and rofecoxib. Continue reading